产品说明
双作用抗血栓形成剂，作为血栓素A2（TXA2）合酶抑制剂和TP受体拮抗剂
该产品包含在以下化合物库中:
质量控制
化学性质
| CAS号 | 284464-77-3 | | |
| 别名 |
| 分子式 | C18H28N4O5S | 分子量 | 412.5 |
| 溶解性 | Soluble in DMSO | 储存条件 | Store at -20° |
实验操作
| 细胞实验[2]： |
| 细胞系 | |
| 溶解方法 | |
| 反应时间 | |
| 应用 | |
| 动物实验[3]： |
| 动物模型 | |
| 剂量 | |
| 注意事项 | |
| References: |
产品描述
IC50: 1.1 nM for TXA2 receptor antagonism
BM 567 is acting as an inhibitor of thromboxane A2 (TXA2) synthase and an antagonist of the TP receptor.
Thromboxane A2 (TXA2), a potent thrombogenic and vasoconstrictor eicosanoid, is produced in large quantities by activated platelets. TXA2 has been reported as a causal factor in the onset of stroke and myocardial infarction.
In vitro: BM 567 was identified as a dual acting antithrombogenic agent, acting as an inhibitor of thromboxane A2 (TXA2) synthase and an antagonist of the TP receptor, the G protein-coupled receptor mediating TXA2 activity in platelets and vascular smooth muscle. BM 567 antagonized the vascular smooth muscle TP receptor with an IC50 value of 1.1 nM. BM 567 was also able to inhibit platelet TX synthase with an IC50 value of 12 nM. In addition, by comparing crystallographic and electronic properties of BM567 and terbogrel, two compounds with dual action (TXRA and TXSI), two essential anchoring identified: sulfonyl and nitro group for BM567 and carboxylate and pyridine nitrogen for terbogrel [1].
In vivo: Up to now, there is no animal in vivo data reported.
Clinical trial: So far, no clinical study has been conducted.
Reference:
[1] Michaux, C. ,Rolin, S.,Dogné, J.M., et al. Structure determination and comparison of BM567, a sulfonylurea, with Terbogrel, two compounds with dual action, thromboxane receptor antagonism, and thromboxane synthase inhibition. Bioorganic & Medicinal Chemistry Letters 11, 1019-1022 (2001).
温馨提示：不可用于临床治疗。